LYMPHOMA: Edited by Dominique BronCurrent treatment options for nodular lymphocyte-predominant Hodgkin lymphomaEichenauer, Dennis A.a,b; Engert, Andreasa,bAuthor Information aUniversity of Cologne, First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf bGerman Hodgkin Study Group (GHSG), First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany Correspondence to Dennis A. Eichenauer, MD, First Department of Internal Medicine, University Hospital Cologne, D-50937 Cologne, Germany. Tel: +0049 0 221 478 42770; fax: +0049 0 221 478 88188; e-mail: [email protected] Current Opinion in Oncology: September 2021 - Volume 33 - Issue 5 - p 395-399 doi: 10.1097/CCO.0000000000000774 Buy Metrics Abstract Purpose of review Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare B cell-derived malignancy. This review aims at providing an overview of recent developments in the management of NLPHL. Recent findings Patients with stage IA NLPHL without risk factors have excellent outcomes. The 8-year progression-free survival (PFS) is roughly 90% and the 8-year overall survival (OS) close to 100% after limited-field radiotherapy (RT) alone. Individuals presenting with early stages other than stage IA without risk factors and intermediate stages have 10-year PFS rates in excess of 70% and 10-year OS rates exceeding 90% when treated with 2 and 4 cycles of ABVD, respectively, followed by consolidation RT. In advanced NLPHL, different protocols such as BEACOPP, ABVD, and R-CHOP have been evaluated retrospectively. However, the optimal approach is undefined. Patients with relapsed NLPHL mostly receive single-agent anti-CD20 antibody treatment or conventional chemotherapy. High-dose chemotherapy and autologous stem cell transplantation are restricted to high-risk patients. NLPHL recurrence is salvaged successfully in the majority of cases. Summary Patients with NLPHL have a very good prognosis. Treatment differs from classical Hodgkin lymphoma in some situations. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.